Memorioal Sloan Kettering Cancer Center
Welcome,         Profile    Billing    Logout  
 9 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schoder, Heiko
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
69
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/24
08/24
NCT05093335: In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET

Recruiting
1
20
US
[68Ga]-Pentixafor
Memorial Sloan Kettering Cancer Center, Pentixapharm AG
Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease, Rosai-Dorfman Disease
10/25
10/25
NCT04030338: Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Active, not recruiting
N/A
58
US
18F-DCFPyL-iPSMA, 68Ga-HBED-iPSMA, PET/CT scan
Memorial Sloan Kettering Cancer Center, Progenics Pharmaceuticals, Inc.
Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Metastatic Prostate Cancer
07/25
07/25
Jhaveri, Komal
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Active, not recruiting
2
30
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex
Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center
Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
08/24
04/26
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Active, not recruiting
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
09/24
NCT04872608: A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Withdrawn
1b
28
US
Letrozole, Palbociclib, Onapristone ER
Memorial Sloan Kettering Cancer Center, Context Therapeutics Inc.
Metastatic Breast Cancer, Unresectable Breast Cancer
04/23
04/23
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Active, not recruiting
1
174
Canada, US, RoW
ZW49
Zymeworks Inc.
HER2-expressing Cancers
08/25
08/25
DESTINY-Breast08, NCT04556773: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer
Checkmark Initial efficacy/safety data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer at ASCO 2022
Jun 2022 - Jun 2022: Initial efficacy/safety data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer at ASCO 2022
Active, not recruiting
1
138
Europe, Canada, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Durvalumab, MEDI4736, Paclitaxel, Taxol A, Capivasertib, AZD5363, Anastrozole, Anastrozol, Fulvestrant, Capecitabine
AstraZeneca, Daiichi Sankyo Co., Ltd., Daiichi Sankyo Company, Limited
Metastatic Breast Cancer
08/23
11/25
SchÓ§der, Heiko
No trials found
Lai, W Victoria
No trials found

Download Options